Clinical Trial Update: Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC [NA]

View source ↗

Summary

This clinical trial update describes a neoadjuvant study combining thymosin alpha-1 with immuno-chemotherapy for resectable non-small cell lung cancer, which is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Thymosin alpha-1 (thymosin alpha-1)

Snippet

Sponsor: Xuanwu Hospital, Beijing | Conditions: Resectable Non-Small-Cell Lung Cancer | NA | Status: NOT_YET_RECRUITING